

# ChemComm

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

*Accepted Manuscripts* are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx


## COMMUNICATION

Direct Asymmetric Hydrogenation of  $\alpha$ -Keto Acids by Using the Highly Efficient Chiral Spiro Iridium CatalystsPu-Cha Yan,<sup>a</sup> Jian-Hua Xie,<sup>b,c</sup> Xiang-Dong Zhang,<sup>a</sup> Kang Chen,<sup>a</sup> Yuan-Qiang Li,<sup>a</sup> Qi-Lin Zhou,<sup>\*b,c</sup> and Da-Qing Che<sup>\*,a,c</sup>Received (in XXX, XXX) Xth XXXXXXXXX 20XX, Accepted Xth XXXXXXXXX 20XX  
DOI: 10.1039/b000000xA new efficient and highly enantioselective direct asymmetric hydrogenation of  $\alpha$ -keto acids employing the Ir/SpiroPAP catalyst under mild reaction conditions has been developed.This method might be feasible for the preparation of a series of chiral  $\alpha$ -hydroxy acids in large scale.

Optically active  $\alpha$ -hydroxy acids and their derivatives are of considerable significance as chiral building blocks in numerous pharmaceuticals and chemical industries,<sup>1</sup> and also are utilized as resolving agents.<sup>2</sup> Therefore various methodologies have been developed for preparing optical pure  $\alpha$ -hydroxy acids, including the enantioselective reduction of prochiral  $\alpha$ -keto esters,<sup>3</sup> kinetic resolution of racemic  $\alpha$ -hydroxy esters,<sup>4</sup> enzymatic or biomimetic methods,<sup>5</sup> Cannizzaro reactions,<sup>6</sup> Friedel-Crafts reactions,<sup>7</sup> synthesis of cyanohydrins as precursors,<sup>8</sup> and hydrogen mediated reductive C-C bond formation reactions.<sup>9</sup> The transition metal catalyzed asymmetric hydrogenation proved to be an efficient and economically feasible method for preparing these important chiral compounds.<sup>10</sup> Although a few papers are devoted to the development of straight forward procedures involving the direct conversion of  $\alpha$ -keto acids to chiral  $\alpha$ -hydroxy acids, the direct asymmetric hydrogenation of  $\alpha$ -keto acids has rarely attracted attention.<sup>11</sup> To the best of our knowledge, only one example was reported so far employing Ru-Sunphos catalyst for the conversion of (*E*)-2-oxo-4-arylbut-3-enoic acids and 2-oxo-4-arylbutanoic acids directly into optically active 2-hydroxy-4-arylbutanoic acids in up to 89.5% ee and 92.6% ee respectively.<sup>12</sup> Therefore, the development of effective, high enantioselective, and direct approaches to  $\alpha$ -hydroxy acids is still of significance.

Be different from  $\alpha$ -keto ester, the  $\alpha$ -keto acid has a carboxyl group which might competitively coordinate to the center metal and then cause deactivation of the catalyst, thus resulting in low enantioselectivity and reactivity. On the other hand, the hydrogenation product ( $\alpha$ -hydroxy acid) usually serves as a ligand, restricting its liberation from the catalyst.<sup>12</sup> The chiral iridium catalysts containing SpiroPAP ligands (Ir/SpiroPAP) developed by Xie and Zhou in 2011, have shown excellent enantioselectivity and reactivity in the hydrogenation of simple ketones and  $\beta$ -aryl  $\beta$ -ketoesters,<sup>13</sup> however, the hydrogenation of  $\alpha$ -phenyl  $\alpha$ -keto ester gave almost racemic product. Recently, we successfully applied these catalysts for the hydrogenation of *m*-hydroxyacetophenone in the presence of more than one equiv base obtaining high enantioselectivity (up to 97% ee) and an high


TON (as high as 100,000).<sup>14</sup> On the basis of this work, we speculate that the same strategy seems to be working in the direct hydrogenation of  $\alpha$ -keto acids. Herein we report that the Ir/SpiroPAP (**1**) catalyzed direct asymmetric hydrogenation of  $\alpha$ -keto acids (**2**) to provide the chiral  $\alpha$ -hydroxy acids (**3**) with excellent enantioselectivity (up to 99.2% ee) and high TON (as high as 50,000) under mild reaction conditions (Scheme 1).

Scheme 1. Asymmetric hydrogenation of  $\alpha$ -keto acids with Ir/SpiroPAP catalysts.

As revealed in Table 1, we employed benzoylformic acid (**2a**) as the model substrate to optimize the reaction conditions. The effects of base quantity, solvents and ligands on reactivity and enantioselectivity were screened. Hydrogenation of **2a** was initially carried out under similar conditions previously optimized for the reaction of  $\beta$ -aryl  $\beta$ -keto esters ((*R*)-**1b**, S/C = 1000, 0.05 equiv base, 15 atm H<sub>2</sub>, 25–30 °C).<sup>13b</sup> However, only trace product was obtained within 24 h (Table 1, entry 1). The same result was observed even when 0.5 equiv *t*BuOK was added (Table 1, entry 2). Dramatically improved reactivity was obtained when 1.0 equiv *t*BuOK was used, the hydrogenation reaction could be completed smoothly within 10 h, giving (*S*)-**3a** in 87% ee (Table 1, entry 3). We speculated that the catalyst might be activated with a relatively weak base such as carboxylic acid potassium salt. The reaction rate could be accelerated by adding 1.06 equiv *t*BuOK, and the full conversion was obtained within 2 h (Table 1, entry 4). Solvent screening showed that *n*-butanol gave the best enantioselectivity (Table 1, entries 5–8). By comparison of various chiral SpiroPAP ligands, it was found that the introduction of an alkyl group at the 6- position of the

pyridine ring of the ligand reduced the enantioselectivity (compare entry 12 with entry 9), however, the presence of an alkyl group at either the 3- or 4- position of the pyridine ring could increase the enantioselectivity (compare entries 8 and 10 with entry 9). Increasing the substrate concentration from 0.4 M to 1.0 M resulted in slightly lower enantioselectivity (Table 1, entry 11). Based on the above results, the optimized reaction conditions were therefore set as follows: 0.1 mol% of (*R*)-**1c** as the catalyst, 1.06 equiv <sup>t</sup>BuOK as base, <sup>n</sup>BuOH as the solvent with a substrate concentration of 0.4 M at room temperature.<sup>15</sup>

**Table 1:** Asymmetric hydrogenation of benzoylformic acid (**2a**). Optimizing reaction conditions.<sup>a</sup>




Entry	( <i>R</i> )- <b>1</b>	B/S <sup>b</sup>	Solvent	Time (h)	Conv. <sup>c</sup> (%)	Ee <sup>d</sup> (%)
1	<b>1b</b>	0.05	EtOH	24	trace	n.d. <sup>e</sup>
2	<b>1b</b>	0.5	EtOH	24	trace	n.d. <sup>e</sup>
3	<b>1b</b>	1.0	EtOH	10	100	87 ( <i>S</i> )
4	<b>1b</b>	1.06	EtOH	2	100	87 ( <i>S</i> )
5	<b>1b</b>	1.06	MeOH	21	92	78 ( <i>S</i> )
6	<b>1b</b>	1.06	<sup>i</sup> PrOH	20	100	87 ( <i>S</i> )
7	<b>1b</b>	1.06	<sup>n</sup> PrOH	2	100	88 ( <i>S</i> )
8	<b>1b</b>	1.06	<sup>n</sup> BuOH	2	100	89 ( <i>S</i> )
9	<b>1a</b>	1.06	<sup>n</sup> BuOH	3	100	85 ( <i>S</i> )
10	<b>1c</b>	1.06	<sup>n</sup> BuOH	1.5	100	93 ( <i>S</i> )
11 <sup>f</sup>	<b>1c</b>	1.06	<sup>n</sup> BuOH	1.5	100	91 ( <i>S</i> )
12	<b>1d</b>	1.06	<sup>n</sup> BuOH	2	100	83 ( <i>S</i> )

<sup>a</sup> Reaction conditions unless otherwise noted: 2.0 mmol scale, [substrate] = 0.4 M, (*R*)-**1** (0.1 mol%), Solvent (5.0 mL), 15 atm H<sub>2</sub>, room temperature (25–30 °C). <sup>b</sup> Base to substrate ratio. <sup>c</sup> Determined by <sup>1</sup>H NMR spectroscopy. <sup>d</sup> Determined by HPLC analysis on a chiral OD-H column of the corresponding methyl ester. The absolute configuration of **3a** is *S* by comparing the specific rotation with reported data. <sup>e</sup> n.d. = not determined. <sup>f</sup> [substrate] = 1.0 M, Solvent (2.0 mL).

Under the optimal reaction conditions, we examined the scope of substrate (Table 2). A series of  $\alpha$ -keto acids (**2a-p**) were hydrogenated to afford the corresponding chiral  $\alpha$ -hydroxy acids (**3a-p**) in high yield (92–98%) and moderate to excellent enantioselectivity (56–99.2% ee). The results summarized in Table 2 indicate that the influence of electronic properties is not obvious, substrates with electron-donating substituents only gave a little better enantioselectivity than those with electron-withdrawing substituents. Apparently, steric hindrance played a crucial role in the asymmetric hydrogenation of these substrates. For the  $\alpha$ -aryl- $\alpha$ -keto acids, *ortho*-substituted benzoylformic acid usually reacted rapidly and gave higher ee values (Table 2, entries

2–4 vs entries 5–11). For more sterically hindered *o*-methylbenzoylformic acid (**2c**), the hydrogenation was extremely fast and high enantioselective. Full conversion was completed within 1 hour to give the (*S*)-2-hydroxy-2-(*o*-tolyl)acetic acid (**3c**) in 98% ee (Table 2, entry 3). This was further supported by the fact that the highest enantioselectivity (99.2% ee) was obtained when 2-(naphthalen-1-yl)-2-oxoacetic acid (**2l**) was employed as the substrate (Table 2, entry 12). It is worth noting that only sporadic papers have been reported on the asymmetric hydrogenation of *ortho*-substituted benzoylformic esters and the enantioselectivities were usually not very high.<sup>3k, 3n, 16</sup>

**Table 2:** Asymmetric hydrogenation of  $\alpha$ -keto acids **2** with (*R*)-**1c**.<sup>a</sup>




Entry	R	<b>3</b>	Time (h)	Yield <sup>b</sup> (%)	Ee <sup>c</sup> (%)
1	C <sub>6</sub> H <sub>5</sub>	<b>3a</b>	1.5	96	93 ( <i>S</i> )
2	2-Cl-C <sub>6</sub> H <sub>4</sub>	<b>3b</b>	1	93	91 ( <i>S</i> )
3	2-Me-C <sub>6</sub> H <sub>4</sub>	<b>3c</b>	1	98	98 ( <i>S</i> )
4	2-OMe-C <sub>6</sub> H <sub>4</sub>	<b>3d</b>	3	97	92 ( <i>S</i> )
5	3-Cl-C <sub>6</sub> H <sub>4</sub>	<b>3e</b>	5	94	91 ( <i>S</i> )
6	3-Me-C <sub>6</sub> H <sub>4</sub>	<b>3f</b>	3	95	92 ( <i>S</i> )
7	3-OMe-C <sub>6</sub> H <sub>4</sub>	<b>3g</b>	4	97	94 ( <i>S</i> )
8	4-F-C <sub>6</sub> H <sub>4</sub>	<b>3h</b>	5	94	90 ( <i>S</i> )
9	4-Cl-C <sub>6</sub> H <sub>4</sub>	<b>3i</b>	4	97	88 ( <i>S</i> )
10	4-Me-C <sub>6</sub> H <sub>4</sub>	<b>3j</b>	4	97	90 ( <i>S</i> )
11	4-OMe-C <sub>6</sub> H <sub>4</sub>	<b>3k</b>	8	96	90 ( <i>S</i> )
12	1-Naphthyl	<b>3l</b>	1	98	99.2 ( <i>S</i> )
13	2-Naphthyl	<b>3m</b>	12	98	91 ( <i>S</i> ) 95 ( <i>S</i> ) <sup>d</sup>
14	Ph(CH <sub>2</sub> ) <sub>2</sub>	<b>3n</b>	1	96	56 ( <i>S</i> ) <sup>e</sup>
15	Cyclohexyl	<b>3o</b>	2	95	82 ( <i>S</i> ) <sup>f</sup>
16 <sup>g</sup>	<sup>t</sup> Bu	<b>3p</b>	21	92	77 ( <i>R</i> ) <sup>f</sup> 85 ( <i>R</i> ) <sup>d,f</sup>

<sup>a</sup> Reaction conditions unless otherwise noted: 2.0 mmol scale, [substrate] = 0.4 M, (*R*)-**1c** (0.1 mol%, S/C = 1000), <sup>n</sup>BuOH (5.0 mL), 15 atm H<sub>2</sub>, room temperature (25–30 °C). <sup>b</sup> Isolated yield. <sup>c</sup> Determined by HPLC analysis on a chiral OD-H or AD-H column of the corresponding methyl ester. The absolute configuration was determined by comparing the specific rotation with reported data. <sup>d</sup> (*R*)-**1b** was used as catalyst. <sup>e</sup> Determined by HPLC analysis on a chiral OD-H column of the corresponding ethyl ester. <sup>f</sup> Determined by HPLC analysis on a chiral OD-H column of the corresponding benzyl ester. <sup>g</sup> 0.2 mol% catalyst was used (S/C = 500).

The hydrogenation of 2-(naphthalen-2-yl)-2-oxoacetic acid (**2m**)

provided direct access to **3m** in 91% ee. When (*R*)-**1b** was used as catalyst, **3m** was obtained in 95% ee (Table 2, entry 13). Longer reaction time was needed presumably due to the poor solubility of the corresponding carboxylic acid potassium salt. Aliphatic  $\alpha$ -hydroxy acids were also obtained in high yield, albeit with only moderate to good enantioselectivities (56-85% ee, Table 2, entry 14-16). For more sterically hindered 3,3-dimethyl-2-oxobutanoic acid (**2p**), the hydrogenation was extremely sluggish even when 0.2 mol% catalyst was used (Table 2, entry 16). Interestingly, the absolute configuration of **3p** was opposite to that of other products.

The fast reaction rate of *o*-chlorobenzoylformic acid (**2b**) prompted us to develop a practical preparation of optical pure *o*-chloromandelic acid which is a key intermediate for a platelet aggregation inhibitor named Clopidogrel<sup>17</sup> with high TON. When the substrate/catalyst ratio was increased to 50,000 (Scheme 2), the hydrogenation of **2b** completed at room temperature under an initial hydrogen pressure of 30 atm within 24 h without loss of enantioselectivity. The ee value of **3b** could be upgraded to >99% by crystallization from toluene in 80% yield. This is a promising procedure for a large-scale or even industrial setting.



**Scheme 2.** Asymmetric hydrogenation of *o*-chlorobenzoylformic acid with high TON.

## Conclusions

In summary, we have developed a new efficient and highly enantioselective direct asymmetric hydrogenation of  $\alpha$ -keto acids into optically active  $\alpha$ -hydroxy acids employing the Ir/SpiroPAP catalyst. The achieved catalyst performance (ee, TON) indicated that this method might be feasible for the preparation of a series of chiral  $\alpha$ -hydroxy acids especially *ortho*-substituted  $\alpha$ -hydroxy phenylacetic acids in large scale. Further investigations are focused on the application of this methodology to the synthesis of chiral pharmaceuticals.

We thank the National Natural Science Foundation of China, the National Basic Research Program of China (973 Program, No. 2012CB821600), “111” Project of the Ministry of Education of China (Grant No. B06005) for financial support.

## Notes and references

- <sup>a</sup> Zhejiang Jiuzhou Pharmaceutical Co., Ltd., 99 Waisha Road, Jiaojiang District, Taizhou City, Zhejiang Province, 318000, P. R. China. Fax: 0086-0571-87000702; Tel: 0086-0571-87000701; E-mail: dqche@zjbz.cn
- <sup>b</sup> State Key Laboratory and Institute of Elemento-organic Chemistry, Nankai University, Tianjin 300071, P. R. China. Fax: 0086-022-23500011; Tel: 0086-022-23500011; E-mail: qlzhou@nankai.edu.cn
- <sup>c</sup> Collaborative Innovation Center of Chemical Science and Engineering (Tianjin), Tianjin 300071, P. R. China. Fax: 0086-022-23500011; Tel: 0086-022-23500011.

† Electronic Supplementary Information (ESI) available: Experimental procedures, characterization data of compounds, <sup>1</sup>H and <sup>13</sup>C NMR spectra, and HPLC charts. See DOI: 10.1039/b000000x/

- (a) G. M. Coppola and H. F. Schuster,  *$\alpha$ -Hydroxy Acids in Enantioselective Synthesis*; VCH: Weinheim, Germany, 1997; (b) *Comprehensive Asymmetric Catalysis*; E. N. Jacobsen, A. Pfaltz and H. Yamamoto, Springer: Berlin, Germany, 1999; Vols. I-III. (c) *Catalysis Asymmetric Synthesis*, 2nd ed.; I. Ojima, Wiley-VCH: New York, 2000.
- K. Kinbara, *Synlett*, 2005, 732.
- For representative examples, see: (a) H. C. Brown and G. G. Pai, *J. Org. Chem.*, 1985, **50**, 1384; (b) V. K. Singh, *Synthesis*, 1992, 605; (c) Z. Wang, B. La, J. M. Fortunak, X.-J. Meng and G. W. Kabalka, *Tetrahedron Lett.*, 1998, **39**, 5501; (d) P. V. Ramachandran, S. Pitre and H. C. Brown, *J. Org. Chem.*, 2002, **67**, 5315; (e) D. Enders, B. A. Stöckel and A. Rembiak, *Chem. Commun.*, 2014, **50**, 4489; (f) I. Solodin, Y. Goldberg, G. Zelčans and E. Lukevics, *J. Chem. Soc., Chem. Commun.*, 1990, 1321; (g) Y. B. Xiang, K. Snow and M. Belley, *J. Org. Chem.*, 1993, **58**, 993; (h) P. Scafato, L. Leo, S. Superchi and C. Rosini, *Tetrahedron*, 2002, **58**, 153; (i) C. Pasquier, J. Eilers, I. Reiners, J. Martens, A. Mortreux and F. Agbossou, *Synlett*, 1998, 1162; (j) L. Qiu, F. Y. Kwong, J. Wu, W. H. Lam, S. Chan, W.-Y. Yu, Y.-M. Li, R. Guo, Z. Zhou and A. S. C. Chan, *J. Am. Chem. Soc.*, 2006, **128**, 5955; (k) C.-J. Wang, X. Sun and X. Zhang, *Synlett*, 2006, 1169; (l) J. W. Yang and B. List, *Org. Lett.*, 2006, **8**, 5653; (m) X. Sun, L. Zhou, W. Li and X. Zhang, *J. Org. Chem.*, 2008, **73**, 1143; (n) Q. Meng, Y. Sun, V. Ratovelomanana-Vidal, J. P. Genêt and Z. Zhang, *J. Org. Chem.*, 2008, **73**, 3842; (o) H. U. Blaser, H. P. Jalett, M. Müller and M. Studer, *Catal. Today*, 1997, **37**, 441; (p) X. Zuo, H. Liu, D. Guo and X. Yang, *Tetrahedron*, 1999, **55**, 7787; (q) M. Studer, H.-U. Blaser and C. Exner, *Adv. Synth. Catal.*, 2003, **345**, 45; (r) L. Xing, F. Du, J.-J. Liang, Y.-S. Chen and Q.-L. Zhou, *J. Mol. Catal. A: Chem.*, 2007, **276**, 191; (s) T. Mallat, E. Orglmeister and A. Baiker, *Chem. Rev.*, 2007, **107**, 4863.
- (a) L. Tang and L. Deng, *J. Am. Chem. Soc.*, 2002, **124**, 2870; (b) A. T. Radosevich, C. Musich and F. D. Toste, *J. Am. Chem. Soc.*, 2005, **127**, 1090; (c) A. Sakakura, S. Umemura and K. Ishihara, *Synlett*, 2009, 1647; (d) S. K. Alamsetti and G. Sekar, *Chem. Commun.*, 2010, **46**, 7235.
- For representative examples, see: (a) N. Kanomata and T. Nakata, *J. Am. Chem. Soc.*, 2000, **122**, 4563; (b) D. Zhu, Y. Yang and L. Hua, *J. Org. Chem.*, 2006, **71**, 4202; (c) M. Landwehr, L. Hochrein, C. R. Otey, A. Kasrayan, J.-E. Backvall and F. H. Arnold, *J. Am. Chem. Soc.*, 2006, **128**, 6058; (d) T. Ema, N. Okita, S. Ide and T. Sakai, *Org. Biomol. Chem.*, 2007, **5**, 1175; (e) R. Kratzer and B. Nidetzky, *Chem. Commun.*, 2007, 1047; (f) G. A. Applegate, R. W. Cheloha, D. L. Nelson and D. B. Berkowitz, *Chem. Commun.*, 2011, **47**, 2420.
- For representative examples, see: (a) A. E. Russel, S. P. Miller and J. P. Morken, *J. Org. Chem.*, 2000, **65**, 8381; (b) K. Ishihara, T. Yano and M. Fushimi, *J. Fluorine Chem.*, 2008, **129**, 994; (c) E. Schmitt, I. Schiffrers and C. Bolm, *Tetrahedron Lett.*, 2009, **50**, 3185; (d) P. Wang, W.-J. Tao, X.-L. Sun, S. Liao and Y. Tang, *J. Am. Chem. Soc.*, 2013, **135**, 16849.
- For representative examples, see: (a) N. Gathergood, W. Zhuang and K. A. Jørgensen, *J. Am. Chem. Soc.*, 2000, **122**, 12517; (b) Y. Yuan, X. Wang, X. Li and K. Ding, *J. Org. Chem.*, 2004, **69**, 146; (c) J. Majer, P. Kwiatkowski and J. Jurczak, *Org. Lett.*, 2008, **10**, 2955; (d) J. Majer, P. Kwiatkowski and J. Jurczak, *Org. Lett.*, 2009, **11**, 4636; (e) Y. Yamamoto, T. Shirai and N. Miyaura, *Chem. Commun.*, 2012, **48**, 2803.
- For representative examples, see: (a) Y. Hamashima, D. Sawada, M. Kanai and M. Shibasaki, *J. Am. Chem. Soc.*, 1999, **121**, 2641; (b) N. Kurono, K. Arai, M. Uemura and T. Ohkuma, *Angew. Chem., Int. Ed.*, 2008, **47**, 6643; (c) W. Wang, X. Liu, L. Lin and X. Feng, *Eur. J. Org. Chem.*, 2010, **25**, 4751; (d) N. Kurono, T. Yoshikawa, M. Yamasaki and T. Ohkuma, *Org. Lett.*, 2011, **13**, 1254.
- (a) J.-R. Kong, M.-Y. Ngai and M. J. Krische, *J. Am. Chem. Soc.*, 2006, **128**, 718; (b) C.-W. Cho and M. J. Krische, *Org. Lett.*, 2006, **8**, 3873; (c) M.-Y. Ngai, J.-R. Kong and M. J. Krische, *J. Org. Chem.*, 2007, **72**, 1063.

- 10 (a) J. G. de Vries and C. J. Elsevier, *The Handbook of Homogeneous Hydrogenation*; Wiley-VCH: Weinheim, 2007; (b) W. Tang and X. Zhang, *Chem. Rev.*, 2003, **103**, 3029; (c) J.-H. Xie, Q.-L. Zhou, *Acta Chim. Sinica*, 2012, **70**, 1427.
- 5 11 (a) M.-J. Kim and G. M. Whitesides, *J. Am. Chem. Soc.*, 1988, **110**, 2959; (b) P. V. Ramachandran, G.-M. Chen and H. C. Brown, *Tetrahedron Lett.*, 1996, **37**, 2205; (c) X.-F. Duan and C.-L. Yin, *Synth. Commun.*, 1997, **27**, 825; (d) Z. Wang, B. La and J. M. Fortunak, *Tetrahedron Lett.*, 1998, **39**, 5501; (e) P. V. Ramachandran, H. C. Brown and S. Pitre, *Org. Lett.*, 2001, **3**, 17; (f)
- 10 F. Taran, C. Gauchet, B. Mohar, S. Meunier, A. Valleix, P. Y. Renard, C. Créminon, J. Grassi, A. Wagner and C. Mioskowski, *Angew. Chem., Int. Ed.*, 2002, **41**, 124; (g) P. V. Ramachandran, S. Pitre and H. C. Brown, *J. Org. Chem.*, 2002, **67**, 5315; (h) C. Exner, A. Pfaltz, M. Studer and H.-U. Blaser, *Adv. Synth. Catal.*, 2003, **345**, 1253.
- 12 (a) L. Zhu, Q. Meng, W. Fan, X. Xie and Z. Zhang, *J. Org. Chem.*, 2010, **75**, 6027; (b) L. Zhu, H. Chen, Q. Meng, W. Fan, X. Xie and Z. Zhang, *Tetrahedron*, 2011, **67**, 6186.
- 20 13 (a) J.-H. Xie, X.-Y. Liu, J.-B. Xie, L.-X. Wang and Q.-L. Zhou, *Angew. Chem., Int. Ed.*, 2011, **50**, 7329; (b) J.-H. Xie, X.-Y. Liu, X.-H. Yang, J.-B. Xie, L.-X. Wang and Q.-L. Zhou, *Angew. Chem., Int. Ed.*, 2012, **51**, 201; (c) J.-H. Xie and Q.-L. Zhou, *Acta Chim. Sinica*, 2014, **72**, 778; (d) X.-H. Yang, J.-H. Xie and Q.-L. Zhou, *Org. Chem. Front.*, 2014, **1**, 190.
- 25 14 P.-C. Yan, G.-L. Zhu, J.-H. Xie, X.-D. Zhang, Q.-L. Zhou, Y.-Q. Li, W.-H. Shen and D.-Q. Che, *Org. Process Res. Dev.*, 2013, **17**, 307.
- 15 Other bases such as KOH and K<sub>2</sub>CO<sub>3</sub> were also tried in the hydrogenation of **2a**. When KOH was used under the optimized
- 30 reaction conditions, the hydrogenation completed within 4 hours and gave the product in 92% ee. However, only 13% of conversion was obtained in 24 hours when K<sub>2</sub>CO<sub>3</sub> was used as base under the same reaction conditions.
- 16 (a) J.-P. Genêt, S. Juge, J.-A. Laffitte, C. Pinel and S. Mallart, PCT Int. Appl., WO 9401390A1. *Chem. Abs.*, 1994, **121**, 156763; (b) Y. Sun, X. Wan, J. Wang, Q. Meng, H. Zhang, L. Jiang and Z. Zhang, *Org. Lett.*, 2005, **7**, 5425.
- 35 17 (a) G. Castaldi, G. Barreca and A. Bologna, WO 03093276, 2003; (b) T. Ema, S. Ide, N. Okita and T. Sakai, *Adv. Synth. Catal.*, 2008, **350**, 2039; (c) S.-F. Zhu, Y. Cai, H.-X. Mao, J.-H. Xie and Q.-L. Zhou,
- 40 *Nat. Chem.*, 2010, **2**, 546.